Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elevation Oncology, Inc. (ELEV : NSDQ)

• Company Description    Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $0.37 Daily Weekly Monthly 20 Day Moving Average: 2,361,815 shares Shares Outstanding: 59.22 (millions) Market Capitalization: $21.82 (millions) Beta: 1.48 52 Week High: $3.28 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.86% 16.42% 12 Week 58.15% 27.15% Year To Date -34.50% -37.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 Federal Street Suite 1900 - Boston,MA 02110 USA ph: 716-371-1125 fax: - ir@elevationoncology.com http://www.elevationoncology.com

• General Corporate Information    Officers Joseph J. Ferra, Jr. - President and Chief Executive Officer Steven A. Elms - Chairman Tammy Furlong - Chief Financial Officer R. Michael Carruthers - Director Julie M. Cherrington - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28623U101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 59.22 Most Recent Split Date: (:1) Beta: 1.48 Market Capitalization: $21.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -4.35% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -74.68 12/31/24 - -62.19 ROA 06/30/25 - - 03/31/25 - -48.14 12/31/24 - -41.82 Current Ratio 06/30/25 - - 03/31/25 - 19.40 12/31/24 - 21.21 Quick Ratio 06/30/25 - - 03/31/25 - 19.40 12/31/24 - 21.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.79 12/31/24 - 1.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.67 12/31/24 - 0.52 Debt-to-Capital 06/30/25 - - 03/31/25 - 40.08 12/31/24 - 34.15

Powered by Zacks Investment Research ©